Effect of Platelet-Rich Plasma Injection on Wound Healing After Fistulotomy for Simple Anal Fistula Randomized Controlled Trial (RCT)
PRPIWHAFSAFRCT
1 other identifier
interventional
70
0 countries
N/A
Brief Summary
Anal fistula is a common benign anorectal condition characterized by an abnormal tract between the anal canal and perianal skin, often resulting from cryptoglandular infection. Surgical fistulotomy remains the standard treatment for simple low anal fistulas, with success rates exceeding 90% . However,wound healing following fistulotomy can be prolonged,ranging from 6-10 weeks,which affects patient comfort, quality of life, and return to normal activity (1,2). After a fistulotomy, the tract is laid open, leaving behind a raw wound extending from the anal canal to the perianal skin.Traditionally,this wound is left open to heal by secondary intention(granulation and epithelialization). In marsupialization, the cut wound edges (the mucosa and anoderm/skin) are sutured to the wound base.Thismakesthewoundshallowerandkeepsitopenfordrainage.Itpreventsadeepcavitythat would otherwise take longer to granulate and epithelialize. Marsupialization of the wound edges has been introduced as a modification of standard fistulotomy to improve healing outcomes. Several randomized trials have shown that marsupialization accelerates wound healing (by 1-4 weeks) and preserves sphincter function better compared to leaving the wound open, without increasing recurrence or complications (3,4,5).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Dec 2025
Typical duration for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2025
CompletedFirst Posted
Study publicly available on registry
November 25, 2025
CompletedStudy Start
First participant enrolled
December 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 30, 2027
November 25, 2025
October 1, 2025
1 year
November 18, 2025
November 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Operative time
messure the improvement of operative time between the PRP group and the non PRP group
intra operative
Secondary Outcomes (1)
Post operative pain
12 months
Study Arms (2)
PRP injection
ACTIVE COMPARATORa group of patients with simple anal fistula that will be treated with PRP following fistulotomy
Non PRP group
NO INTERVENTIONthe other group that will be treated with fistulotomy only without PRP
Interventions
Eligibility Criteria
You may qualify if:
- Age18-65years. Both males and females. Clinical diagnosis of simple low anal fistula(confirmed by examination±imaging).
- Simple fistula is defined as:
- Fistula affecting less than one third of anal sphincter Fistula willnot affect sphincter function after surgery(no risk for fecal incontinence).
- All types of low fistula which will not affect anal continence after surgery.
You may not qualify if:
- Complex or high anal fistulas:
- ( multiple tracts, suprasphincteric, extrasphincteric, or high transsphincteric tracts.) -Underlying diseases that impair healing: (Crohn's disease, ulcerative colitis, tuberculosis, HIV infection, anorectal malignancy)
- Hematological disorders: coagulopathy, thrombocytopenia, or platelet dysfunction.
- Systemic factors:
- Uncontrolled diabetes mellitus. Immunosuppressive therapy (e.g., steroids, chemotherapy). Previous surgery for anal fistula (to avoid bias from scar tissue and recurrence)..
- Known allergy to any agents used in PRP preparation (rare, e.g., calcium chloride).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Demonstrator
Study Record Dates
First Submitted
November 18, 2025
First Posted
November 25, 2025
Study Start
December 1, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
November 30, 2027
Last Updated
November 25, 2025
Record last verified: 2025-10